These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 19532078)

  • 1. Cardiovascular disease and HIV infection: host, virus, or drugs?
    Martínez E; Larrousse M; Gatell JM
    Curr Opin Infect Dis; 2009 Feb; 22(1):28-34. PubMed ID: 19532078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
    Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
    AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on cardiovascular complications in HIV infection.
    Currier JS
    Top HIV Med; 2009; 17(3):98-103. PubMed ID: 19675367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.
    Mondy KE; Gottdiener J; Overton ET; Henry K; Bush T; Conley L; Hammer J; Carpenter CC; Kojic E; Patel P; Brooks JT;
    Clin Infect Dis; 2011 Feb; 52(3):378-86. PubMed ID: 21217185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular disease prevention and treatment in patients with human immunodeficiency virus.
    Magen E; Elbirt D; Sthoeger Z
    Isr Med Assoc J; 2005 Apr; 7(4):252-6. PubMed ID: 15847207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increased cardiovascular risk in HIV patients].
    Wierema TK
    Ned Tijdschr Geneeskd; 2010; 154():A788. PubMed ID: 20456808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
    Crook M
    Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.
    Deeks SG
    Top HIV Med; 2009; 17(4):118-23. PubMed ID: 19890183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cardiovascular disease in HIV-infected patients.
    Das S
    J Antimicrob Chemother; 2010 Mar; 65(3):386-9. PubMed ID: 20026610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular disease and toxicities related to HIV infection and its therapies.
    Zareba KM; Miller TL; Lipshultz SE
    Expert Opin Drug Saf; 2005 Nov; 4(6):1017-25. PubMed ID: 16255661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
    Calza L; Manfredi R; Pocaterra D; Chiodo F
    J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral therapy with heart.
    Randell P; Moyle G
    Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial function in HIV-infected patients with low or mild cardiovascular risk.
    Blanco JJ; García IS; Cerezo JG; de Rivera JM; Anaya PM; Raya PG; García JG; López JR; Hernández FJ; Rodríguez JJ
    J Antimicrob Chemother; 2006 Jul; 58(1):133-9. PubMed ID: 16702174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk factors and HIV disease.
    Fedele F; Bruno N; Mancone M
    AIDS Rev; 2011; 13(2):119-29. PubMed ID: 21587343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.